The Learning Objectives for the individual sessions are below:

Week 2 &3 Time to Vent Module 6/1/2020- 6/14/2020 (30 hrs)

• Principles of Mechanical Ventilation
• Simulation session: Mechanical Ventilators
• Ventilator cases
• Acute Respiratory Distress Syndrome
  
  Learning Objectives:
• Accurately define the key terminology concerning mechanical ventilation as outlined by the learning activity and handout review.
• List the similarities and differences among the most commonly used modes of mechanical ventilation.
• Methodically interpret arterial blood gases and propose the necessary changes on a ventilator needed to treat the patient’s underlying pathologic process.
• Describe what initiates the breath (trigger) and what terminates the breath (cycling) in mechanical ventilation.
• Demonstrate a safety focused attitude by utilizing a low tidal volume lung protective strategy on patients with acute respiratory distress syndrome (ARDS) or those at risk of ARDS. 
  
  Week 4 & 5 Circulatory Shock: 6/15-6/28/2020 (30hrs)
• Diagnosis and Hemodynamic monitoring
• Hemodynamics and Flotrac
• Vasoactive agents
• Simulation session: Central line placement/scrubbing and gowning
• Simulation session ABGs and arterial line placement
  
  Learning Objectives:
• Accurately define circulatory shock.
• Outline an approach to classify the categories of shock.
• Describe the main components of hemodynamic monitoring.
• Apply hemodynamics to determine the etiology of shock.
• Describe the various methods of assessing fluid responsiveness in a critically ill patient.
• Discuss the core strategies in managing critically ill patients with shock.
• List the main effects and adverse effects of vasoactive agents.
• Safely place a central line under supervision
• Safely place an arterial line under supervision
• Recall the steps involved in scrubbing and gowning for sterile procedures
• Safely perform an arterial puncture under supervision
  
  Week 6 Sepsis in the ICU 6/29/2020-7/5/2020 (10 hrs)
  
  Learning Objectives:
• Accurately define septic shock.
• Outline an evidence-based approach to evaluate patients with suspected septic shock.
• Describe the assessment of organ dysfunction by using the SOFA score.
• Describe the first and second line vasopressors used in the management of patients with septic shock.
• List the components of the sepsis care bundles as outlined by the surviving sepsis guidelines of 2018.
• Summarize the role of lactic acid in predicting mortality in the setting of sepsis and septic shock.
• Illustrate the ways in which volume status and tissue perfusion can be assessed in septic shock.
  
  Week 7 Analgesia, Sedation and Neuromuscular Blockade 7/6/2020-7/12/2020 (10hrs)

• Analgesia, Sedation and Neuromuscular Blockade

  Learning Objectives:

• Develop an analgesic strategy to treat patients in the critical care setting.
• Evaluate both verbal and non-verbal ICU patients for pain using the Critical Care Pain Observation Tool (CPOT).
• Evaluate both verbal and non-verbal ICU patients for agitation-sedation using the Richmond Agitation-Sedation Scale (RASS).
• Summarize an ideal sedation strategy for critically ill patients based on the recommendations from the 2018 PADIS guidelines.
• Describe the role of neuromuscular blockade in the ICU.
• List the main short and long term adverse effects of commonly used analgesics, sedatives and neuromuscular blocking agents.
  
  Week 8 Delirium in the ICU 7/13/2020-7/19/2020 (10hrs)
  
  Learning Objectives:
• Accurately define Delirium
• List the risk factors for the development of ICU delirium
• Apply the Confusion Assessment Method for Intensive Care Units (CAM- ICU) in identifying patients with delirium.
• Devise a differential diagnosis for possible underlying etiologies of delirium in the critically ill patient
• Describe both non-pharmacologic and pharmacologic strategies used in managing patients with delirium.

Summarize the components of the ABCDEF (A to F) Bundle including its role in improving patient outcomes.

Week 9 Acute Renal Failure in the ICU 7/20/2020-7/26/2020 (10 hrs)

Learning Objectives:

• Accurately define Acute Kidney Injury.
•  Describe the proposed pathophysiology of acute kidney Injury in COVID-19.
• List the commonest causes of Acute Kidney Injury in the ICU.
• Summarize the role of renal replacement therapy ( IHD, PIRRT and CVVH) in the treatment of renal failure in the critical care setting.
• Identify patient who are at risk of renal failure.
• Select strategies to prevent or mitigate the risk of acute renal failure.
• Describe the postulated pathophysiology of AKI in the COVID-19 patient.​

Week 10 Critical Care Ultrasonography 7/27/2020-8/2/2020 (10hrs)

Learning Objectives:

• Accurately compare the main indications and proper patient positioning when using the various ultrasound probes (linear, curvilinear, phased-array) in the critical care setting.
• Differentiate between A-line, B-line artefacts and rib shadow
• Identify the sonographic signs associated with pneumothorax, pleural effusion, pulmonary edema, and consolidation
• Identify some sonographic features that are characteristic of transudative and exudative pleural effusions
• Rapidly acquire ultrasound images of the heart, lungs and abdomen and distinguish between pathologic and normal studies.
• Demonstrate the ability to survey the anatomy as it pertains to the two most commonly performed ultrasound guided invasive procedures in the ICU (central line placement, arterial line placement)
• Identify at least one way that ultrasound makes the above procedures safer.
• Appropriately identify patients in whom ultrasound will assist in diagnosis and clinical problem solving.
• Interpret key findings and clinically relevant images in:
  1.  The Thorax
  2.  A Focused cardiac Exam
  3.  Inferior Vena Cava (volume assessment)
  4.  The assessment of peritoneal fluid (ascites)

Week 11 &12 Final week and CCAPP Presentations 8/3/2020-8/16/2020 (10hrs)

Learning Objectives

• Describe how the six therapeutic agents' mechanism of action.
• Summarize the evidence on the efficacy of the below therapeutic agents specifically in COVID-19.
• State who would benefit the most form each of the therapeutic agents below.
• Outline any adverse risks associated with each of the therapeutic modalities listed below.
  1.  Therapeutic agents:
  2.  Systemic Corticosteroids (Focus on Dexamethasone)
  3.  Antivirals (Focus on Remdesivir)
  4.  Convalescent Plasma
  5.  Anti-IL6 agents (Focus on Toclizumab)
  6.  Pulmonary Vasodilators (Focus on inhaled epoprostenol/ Flolan)​
  7.  Extracorporeal membrane oxygenation